Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21. Following the sale, the chief operating officer directly owned 377,802 shares of the company

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction on Monday, October 19th. The shares were sold at an average price of $24.05, for a total value of $285,738.05. Following the completion of the sale, the chief operating officer directly owned 377,802 shares of the company

Julie Rubinstein exercised options at $12.14 per share. Sales on October 19–21, 2026 followed a trading plan adopted November 18, 2025.

Price-action only: Adaptive Biotechnologies Corporation (ADPT) movements set the tone for institutional models. Why (ADPT) Price Action Is Critical for Tactical Trading

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the company

President and COO Julie Rubinstein traded October 14–16, 2026, under a Rule 10b5-1 trading plan adopted November 18, 2025. Options were fully vested.

Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Management's webcast starts at 1:30 p.m. Pacific (4:30 p.m. Eastern), and the live audio will be archived for replay within 24 hours after the event.